Richard Anthony Parker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Richard Anthony Parker has a total of 369 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Weir
Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
13 shared publications Andrew Stoddart
Edinburgh Clinical Trials Unit, Usher Institute, The University of Edinburgh, Edinburgh, UK
5 shared publicationsHilary Pinnock
Usher Institute, University of Edinburgh, Edinburgh, UK
5 shared publications- Rustam Al-Shahi Salman
Institute for Neuroscience and Cardiovascular Research, The University of Edinburgh, Edinburgh, UK
5 shared publications Brian McKinstry
Usher Institute, University of Edinburgh, Edinburgh, UK
4 shared publicationsPaul Padfield
Usher Institute, University of Edinburgh, Edinburgh, UK
4 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-18
Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
Background: Optimising comfort and ability to communicate for mechanically ventilated intensive care unit patients is a priority for clinicians, intensive care unit patients and their relatives. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2-agonists dexmedetomidine and clonidine are potential alternative sedatives. Objective(s): To explore whether nurses and relatives perceive patients sedated with dexmedetomidine and/or clonidine appear more awake, comfortable and co-operative than patients receiving only propofol-based sedation. Design and methods: Substudy within an open-label, three-arm trial. Setting and participants: Forty-one intensive care units in the United Kingdom. One thousand four hundred and thirty-seven adults receiving propofol ± opioid for sedation-analgesia within 48 hours of starting mechanical ventilation, expected to require ≥ 48 total hours of mechanical ventilation. Interventions: Light sedation was targeted in all patients unless clinicians requested deeper sedation. In intervention groups, algorithms promoted alpha2-agonist up-titration and propofol down-titration, followed by sedation primarily with allocated alpha2-agonist. Usual care was propofol-based sedation. Intervention continued until patients were successfully extubated (primary outcome), or other pre-defined end points. Outcomes: For each 12-hour care period, nurses responded to two ‘yes/no’ questions: is the patient able to communicate pain? Is the patient able to co-operate with care? When the patients’ personal legal representative visited, they were asked for ‘yes/no’ responses to three questions: does the patient appear awake? Does the patient appear comfortable? Does the visitor feel they can communicate with the patient? Intervention versus propofol group responses were compared fitting a generalised linear mixed model, with results expressed as odds ratios (95% confidence intervals); odds ratios > 1 indicated greater probability of a ‘yes’ response. Results: Nurse responses were available for > 90% of trial patients [mean (standard deviation) 12 (12) care periods per patient]. Comparing dexmedetomidine versus propofol groups, the odds ratio for a ‘yes’ response to ‘ communicate pain ’ was 1.38 (95% confidence interval 1.08 to 1.75), and for clonidine versus propofol, it was 1.13 (0.89 to 1.43). For ‘ co-operate with care ’ comparing dexmedetomidine versus propofol groups, the odds ratio was 1.14 (95% confidence interval 0.98 to 1.32), and for clonidine versus propofol, it was 0.96 (95% confidence interval 0.83 to 1.12). Relative responses were available for 32–34% of trial patients across groups [mean (standard deviation) 3 (3) days per patient]. For the ‘ appear awake ’ question, the dexmedetomidine versus propofol group odds ratio was 1.48 (95% confidence interval 1.04 to 2.10), and for clonidine versus propofol, it was 1.35 (95% confidence interval 0.95 to 1.91). For ‘ appear comfortable ’, the dexmedetomidine versus propofol group odds ratio was 0.64 (95% confidence interval 0.38 to 1.09), and for clonidine versus propofol, it was 0.78 (95% confidence interval 0.45 to 1.34). For the ‘ feel they can communicate ’ comparison, the dexmedetomidine versus propofol group odds ratio was 1.00 (95% confidence interval 0.68 to 1.47), and for clonidine versus propofol, it was 1.05 (95% confidence interval 0.71 to 1.54). Limitations: Interventions were unblinded, with risk of bias; missing data may not have been at random. Conclusions: Nurses perceived patients receiving dexmedetomidine-based sedation could better communicate pain than with propofol-based sedation, and relatives perceived patients appeared more awake. No differences for the other questions were found, or for the clonidine versus propofol comparisons, although some uncertainty remains due to the wide confidence intervals. Future work: Additional mixed-methods research of sedation quality with different agents from staff and relative perspectives. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
- 1 January 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-18
Open AccessRelative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
Background: Optimising comfort and ability to communicate for mechanically ventilated intensive care unit patients is a priority for clinicians, intensive care unit patients and their relatives. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2-agonists dexmedetomidine and clonidine are potential alternative sedatives. Objective(s): To explore whether nurses and relatives perceive patients sedated with dexmedetomidine and/or clonidine appear more awake, comfortable and co-operative than patients receiving only propofol-based sedation. Design and methods: Substudy within an open-label, three-arm trial. Setting and participants: Forty-one intensive care units in the United Kingdom. One thousand four hundred and thirty-seven adults receiving propofol ± opioid for sedation-analgesia within 48 hours of starting mechanical ventilation, expected to require ≥ 48 total hours of mechanical ventilation. Interventions: Light sedation was targeted in all patients unless clinicians requested deeper sedation. In intervention groups, algorithms promoted alpha2-agonist up-titration and propofol down-titration, followed by sedation primarily with allocated alpha2-agonist. Usual care was propofol-based sedation. Intervention continued until patients were successfully extubated (primary outcome), or other pre-defined end points. Outcomes: For each 12-hour care period, nurses responded to two ‘yes/no’ questions: is the patient able to communicate pain? Is the patient able to co-operate with care? When the patients’ personal legal representative visited, they were asked for ‘yes/no’ responses to three questions: does the patient appear awake? Does the patient appear comfortable? Does the visitor feel they can communicate with the patient? Intervention versus propofol group responses were compared fitting a generalised linear mixed model, with results expressed as odds ratios (95% confidence intervals); odds ratios > 1 indicated greater probability of a ‘yes’ response. Results: Nurse responses were available for > 90% of trial patients [mean (standard deviation) 12 (12) care periods per patient]. Comparing dexmedetomidine versus propofol groups, the odds ratio for a ‘yes’ response to ‘ communicate pain ’ was 1.38 (95% confidence interval 1.08 to 1.75), and for clonidine versus propofol, it was 1.13 (0.89 to 1.43). For ‘ co-operate with care ’ comparing dexmedetomidine versus propofol groups, the odds ratio was 1.14 (95% confidence interval 0.98 to 1.32), and for clonidine versus propofol, it was 0.96 (95% confidence interval 0.83 to 1.12). Relative responses were available for 32–34% of trial patients across groups [mean (standard deviation) 3 (3) days per patient]. For the ‘ appear awake ’ question, the dexmedetomidine versus propofol group odds ratio was 1.48 (95% confidence interval 1.04 to 2.10), and for clonidine versus propofol, it was 1.35 (95% confidence interval 0.95 to 1.91). For ‘ appear comfortable ’, the dexmedetomidine versus propofol group odds ratio was 0.64 (95% confidence interval 0.38 to 1.09), and for clonidine versus propofol, it was 0.78 (95% confidence interval 0.45 to 1.34). For the ‘ feel they can communicate ’ comparison, the dexmedetomidine versus propofol group odds ratio was 1.00 (95% confidence interval 0.68 to 1.47), and for clonidine versus propofol, it was 1.05 (95% confidence interval 0.71 to 1.54). Limitations: Interventions were unblinded, with risk of bias; missing data may not have been at random. Conclusions: Nurses perceived patients receiving dexmedetomidine-based sedation could better communicate pain than with propofol-based sedation, and relatives perceived patients appeared more awake. No differences for the other questions were found, or for the clonidine versus propofol comparisons, although some uncertainty remains due to the wide confidence intervals. Future work: Additional mixed-methods research of sedation quality with different agents from staff and relative perspectives. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
- Open Access
- 1 November 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-18
An exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT
Background: Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required. Aim and objectives: The aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care. Design and methods: A mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention’s fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial’s logic model, lasted 45–60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial. Results: Site intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience. Limitations: Due to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews. Conclusion: Optimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations. Future work: Findings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
- 1 November 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-18
Open AccessAn exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT
Background: Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required. Aim and objectives: The aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care. Design and methods: A mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention’s fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial’s logic model, lasted 45–60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial. Results: Site intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience. Limitations: Due to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews. Conclusion: Optimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations. Future work: Findings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
- Open Access
- 1 March 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-21
Developing a Randomised Efficacy PREcision medicine Platform trial design for Cavernomas: the CARE PREP study
Background: Symptomatic cerebral cavernous malformations are a rare sporadic or familial disease, which may cause haemorrhagic strokes or epileptic seizures. In 2015, a James Lind Alliance Priority Setting Partnership ranked targeted drug therapies as fourth of the top 10 research priorities for cerebral cavernous malformations. There are no disease-modifying drugs for cerebral cavernous malformations, but there are several promising candidates with proof of concept in human and animal studies. There are no platform trials for cerebral cavernous malformations. Objectives: (1) Consolidate and initiate international collaborations between cerebral cavernous malformations researchers, cerebral cavernous malformations patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners; (2) Finalise a protocol for an efficient, international platform trial of multiple drugs using precision medicine (sporadic vs. familial cerebral cavernous malformations) that is both feasible and acceptable to patients and regulators; (3) Estimate the research, support and treatment costs of the platform trial and apply to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation Programme. Methods: A National Institute for Health and Care Research Efficacy and Mechanism Evaluation Application Acceleration Award funded this project from September 2022 to August 2023. A trial manager supported the Chief Investigator in growing and leading a multidisciplinary international collaboration, including a patient and public involvement advisory group, in a series of meetings to optimise study design, equality, diversity and inclusion. Edinburgh Innovations established connections with commercial partners with candidate drugs. We assessed feasibility by scoping potential funding agencies, and clinical networks that might support recruitment internationally. We agreed upon a final design and sample size through a process of consensus, enlightened by scenarios simulated by statisticians varying key parameters, which informed a comprehensive estimate of the budget for a stage 1 submission to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Setting: International collaboration. Participants: Clinicians, researchers, patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners. Results: There was one face-to-face meeting, nine virtual meetings of the co-applicants, and five meetings of the patient and public involvement advisory group. We identified 14 countries with clinical leadership, a cerebral cavernous malformation research network, and a funding agency that could support an international trial. We contacted three potential commercial partners and obtained one letter of collaboration. We sent monthly newsletters to collaborators. Our meetings and simulations concluded that a three-arm, two-stage multiarm multistage adaptive treatment selection randomised trial design was suitable for evaluating aspirin and propranolol as the first two interventions compared with standard care in a platform trial. We submitted a stage 1 proposal for this Cavernous malformations A Randomised Efficacy MAster Protocol study to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation call 23/15 in May 2023, and a resubmission was encouraged. Limitations: The National Institute for Health and Care Research Efficacy and Mechanism Evaluation funding committee would have required further justification for the choice of the intermediate phenotype used for treatment selection, biomarker validation work, and details about the pipeline of interventions. Future work: We have addressed these limitations and re-applied to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR153811.
- 1 March 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-21
Open AccessDeveloping a Randomised Efficacy PREcision medicine Platform trial design for Cavernomas: the CARE PREP study
Background: Symptomatic cerebral cavernous malformations are a rare sporadic or familial disease, which may cause haemorrhagic strokes or epileptic seizures. In 2015, a James Lind Alliance Priority Setting Partnership ranked targeted drug therapies as fourth of the top 10 research priorities for cerebral cavernous malformations. There are no disease-modifying drugs for cerebral cavernous malformations, but there are several promising candidates with proof of concept in human and animal studies. There are no platform trials for cerebral cavernous malformations. Objectives: (1) Consolidate and initiate international collaborations between cerebral cavernous malformations researchers, cerebral cavernous malformations patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners; (2) Finalise a protocol for an efficient, international platform trial of multiple drugs using precision medicine (sporadic vs. familial cerebral cavernous malformations) that is both feasible and acceptable to patients and regulators; (3) Estimate the research, support and treatment costs of the platform trial and apply to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation Programme. Methods: A National Institute for Health and Care Research Efficacy and Mechanism Evaluation Application Acceleration Award funded this project from September 2022 to August 2023. A trial manager supported the Chief Investigator in growing and leading a multidisciplinary international collaboration, including a patient and public involvement advisory group, in a series of meetings to optimise study design, equality, diversity and inclusion. Edinburgh Innovations established connections with commercial partners with candidate drugs. We assessed feasibility by scoping potential funding agencies, and clinical networks that might support recruitment internationally. We agreed upon a final design and sample size through a process of consensus, enlightened by scenarios simulated by statisticians varying key parameters, which informed a comprehensive estimate of the budget for a stage 1 submission to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Setting: International collaboration. Participants: Clinicians, researchers, patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners. Results: There was one face-to-face meeting, nine virtual meetings of the co-applicants, and five meetings of the patient and public involvement advisory group. We identified 14 countries with clinical leadership, a cerebral cavernous malformation research network, and a funding agency that could support an international trial. We contacted three potential commercial partners and obtained one letter of collaboration. We sent monthly newsletters to collaborators. Our meetings and simulations concluded that a three-arm, two-stage multiarm multistage adaptive treatment selection randomised trial design was suitable for evaluating aspirin and propranolol as the first two interventions compared with standard care in a platform trial. We submitted a stage 1 proposal for this Cavernous malformations A Randomised Efficacy MAster Protocol study to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation call 23/15 in May 2023, and a resubmission was encouraged. Limitations: The National Institute for Health and Care Research Efficacy and Mechanism Evaluation funding committee would have required further justification for the choice of the intermediate phenotype used for treatment selection, biomarker validation work, and details about the pipeline of interventions. Future work: We have addressed these limitations and re-applied to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR153811.
- Open Access
- 2 December 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 178, 111622
A systematic review of stepped wedge cluster randomized trials in high impact journals: assessing the design, rationale, and analysis
- 2 December 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 178, 111622
Open AccessA systematic review of stepped wedge cluster randomized trials in high impact journals: assessing the design, rationale, and analysis
- Open Access
- 1 November 2024
- Published by National Institute for Health and Care Research in Public Health Research
- Vol. 12 (11) , 1-186
A self-efficacy enhancement alcohol reduction intervention for men on-remand in prison: the APPRAISE feasibility pilot RCT
Background: As many as 70% of remand prisoners have admitted to being under the influence of alcohol when committing the crime leading to their imprisonment. Providing support and advice regarding alcohol consumption can be effective in some groups of people. There is little evidence regarding this for men on remand in prison. Objective: To pilot the study measures and evaluation methods to assess the feasibility of conducting a future definitive multicentre, pragmatic, parallel group, randomised controlled trial. Design: A two-arm, parallel group, individually randomised pilot study of a self-efficacy-enhancing psychosocial alcohol intervention to reduce levels of alcohol consumption for males on remand in prison and on liberation. Setting: Two purposively selected prisons in Scotland and England. Participants: Adult men on remand in prison with an Alcohol Use Disorders Identification Test score of ≥ 8. Intervention: The APPRAISE intervention delivery comprised four steps: Step 1: 1 × 40-minute face-to-face session, delivered by a trained practitioner from Change Grow Live in prison. Steps 2, 3 and 4: 20-minute sessions conducted by phone, on or as close as possible to days 3, 7 and 21 post liberation. Control: assessment, screening and referral onto further alcohol support options. Main outcome measures: Recruitment and retention rates, completion of follow-ups, outcome measures at 12 months and interventions delivered. The primary outcome for the pilot study was alcohol consumed in the 28 days prior to Time Point 2, assessed using the extended Alcohol Use Disorders Identification Test-C. Results: Of 182 men on remand approached across two study sites, 132 were randomised (90 in England; 42 in Scotland) with 46 randomised to intervention and 44 to care as usual in England and 22 randomised to intervention and 20 to care as usual in Scotland. A total of 53 in-prison interventions were delivered. One day-3 post-liberation intervention was delivered, no day-7 and one day-21. At 12 months, of 132 randomised, 18 (13%) were followed up, 53 (40%) were not liberated; 47 (36%) were uncontactable and 14 (11%) had been released but could not be located. Data completeness was 96% at baseline and 8% at 12 months. The process evaluation reported good acceptability of the intervention with investment in time, capacity and space to support implementation identified. The economic study produced guidance on how to assess costs associated with implementing the APPRAISE intervention which could be applied more broadly. Harms: No adverse events or side effects were noted. Conclusions: A future definitive trial would be possible, but only if follow-up mechanisms can be addressed as well as full access to recidivism and health data. Collaboration with the probation service in future could offer the opportunity to develop a robust process and system to optimise follow-up post liberation. Dedicated resources to support the intervention delivery both in and out of the prison setting are recommended. Limitations: Coronavirus disease discovered in 2019 impacted recruitment and follow-up, with access to prisons restricted. We were unable to deliver the post-liberation element of the intervention. We did not include probation services or other agencies in the trial. Trial registration: This trial is registered as Current Controlled Trials ISRCTN36066. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme (NIHR award ref: 17/44/11) and is published in full in Public Health Research; Vol. 12, No. 11. See the NIHR Funding and Awards website for further award information.
- 1 November 2024
- Published by National Institute for Health and Care Research in Public Health Research
- Vol. 12 (11) , 1-186
Open AccessA self-efficacy enhancement alcohol reduction intervention for men on-remand in prison: the APPRAISE feasibility pilot RCT
Background: As many as 70% of remand prisoners have admitted to being under the influence of alcohol when committing the crime leading to their imprisonment. Providing support and advice regarding alcohol consumption can be effective in some groups of people. There is little evidence regarding this for men on remand in prison. Objective: To pilot the study measures and evaluation methods to assess the feasibility of conducting a future definitive multicentre, pragmatic, parallel group, randomised controlled trial. Design: A two-arm, parallel group, individually randomised pilot study of a self-efficacy-enhancing psychosocial alcohol intervention to reduce levels of alcohol consumption for males on remand in prison and on liberation. Setting: Two purposively selected prisons in Scotland and England. Participants: Adult men on remand in prison with an Alcohol Use Disorders Identification Test score of ≥ 8. Intervention: The APPRAISE intervention delivery comprised four steps: Step 1: 1 × 40-minute face-to-face session, delivered by a trained practitioner from Change Grow Live in prison. Steps 2, 3 and 4: 20-minute sessions conducted by phone, on or as close as possible to days 3, 7 and 21 post liberation. Control: assessment, screening and referral onto further alcohol support options. Main outcome measures: Recruitment and retention rates, completion of follow-ups, outcome measures at 12 months and interventions delivered. The primary outcome for the pilot study was alcohol consumed in the 28 days prior to Time Point 2, assessed using the extended Alcohol Use Disorders Identification Test-C. Results: Of 182 men on remand approached across two study sites, 132 were randomised (90 in England; 42 in Scotland) with 46 randomised to intervention and 44 to care as usual in England and 22 randomised to intervention and 20 to care as usual in Scotland. A total of 53 in-prison interventions were delivered. One day-3 post-liberation intervention was delivered, no day-7 and one day-21. At 12 months, of 132 randomised, 18 (13%) were followed up, 53 (40%) were not liberated; 47 (36%) were uncontactable and 14 (11%) had been released but could not be located. Data completeness was 96% at baseline and 8% at 12 months. The process evaluation reported good acceptability of the intervention with investment in time, capacity and space to support implementation identified. The economic study produced guidance on how to assess costs associated with implementing the APPRAISE intervention which could be applied more broadly. Harms: No adverse events or side effects were noted. Conclusions: A future definitive trial would be possible, but only if follow-up mechanisms can be addressed as well as full access to recidivism and health data. Collaboration with the probation service in future could offer the opportunity to develop a robust process and system to optimise follow-up post liberation. Dedicated resources to support the intervention delivery both in and out of the prison setting are recommended. Limitations: Coronavirus disease discovered in 2019 impacted recruitment and follow-up, with access to prisons restricted. We were unable to deliver the post-liberation element of the intervention. We did not include probation services or other agencies in the trial. Trial registration: This trial is registered as Current Controlled Trials ISRCTN36066. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme (NIHR award ref: 17/44/11) and is published in full in Public Health Research; Vol. 12, No. 11. See the NIHR Funding and Awards website for further award information.
- Open Access
- 2 March 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-4
Response to Letter from Wong on determining the target difference in sample size calculations for randomised controlled trials
- 2 March 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-4
Open AccessResponse to Letter from Wong on determining the target difference in sample size calculations for randomised controlled trials
- Open Access
- 11 September 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-3
The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
Recently, the Blinding of Trial Statisticians research team, Iflaifel and colleagues, have produced detailed guidance regarding the blinding or unblinding of statisticians in clinical trials, based on substantial mixed-methods work. I wish to comment on the research findings. In particular, I argue that open-label trials, non-drug trials, or non-inferiority trials should not be treated any differently from blinded superiority trials with regards to the risk of bias assessment. Prevention of bias should be the priority for definitive randomised controlled trials, regardless of the precise study design.
- 11 September 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-3
Open AccessThe unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
Recently, the Blinding of Trial Statisticians research team, Iflaifel and colleagues, have produced detailed guidance regarding the blinding or unblinding of statisticians in clinical trials, based on substantial mixed-methods work. I wish to comment on the research findings. In particular, I argue that open-label trials, non-drug trials, or non-inferiority trials should not be treated any differently from blinded superiority trials with regards to the risk of bias assessment. Prevention of bias should be the priority for definitive randomised controlled trials, regardless of the precise study design.
- Open Access
- 4 August 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-5
The importance of clinical importance when determining the target difference in sample size calculations
Recently, it was argued that clinically important differences should play no role in sample size calculations. Instead, it was proposed that sample size calculations should focus on setting realistic estimates of treatment benefit. We disagree, and argue in this article that considering the importance of a target difference is necessary in the context of randomised controlled trials of effectiveness, particularly definitive phase III trials. Ignoring clinical importance could have serious ethical and practical consequences.
- 4 August 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-5
Open AccessThe importance of clinical importance when determining the target difference in sample size calculations
Recently, it was argued that clinically important differences should play no role in sample size calculations. Instead, it was proposed that sample size calculations should focus on setting realistic estimates of treatment benefit. We disagree, and argue in this article that considering the importance of a target difference is necessary in the context of randomised controlled trials of effectiveness, particularly definitive phase III trials. Ignoring clinical importance could have serious ethical and practical consequences.
- Open Access
- 16 January 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-15
Statistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART)
Background: MND-SMART is a platform, multi-arm, multi-stage, multi-centre, randomised controlled trial recruiting people with motor neuron disease. Initially, the treatments memantine and trazodone will each be compared against placebo, but other investigational treatments will be introduced into the trial later. The co-primary outcomes are the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R) functional outcome, which is assessed longitudinally, and overall survival. Methods: Initially in MND-SMART, participants are randomised 1:1:1 via a minimisation algorithm to receive placebo or one of the two investigational treatments with up to 531 to be randomised in total. The comparisons between each research arm and placebo will be conducted in four stages, with the opportunity to cease further randomisations to poorly performing research arms at the end of stages 1 or 2. The final ALS-FRS-R analysis will be at the end of stage 3 and final survival analysis at the end of stage 4. The estimands for the co-primary outcomes are described in detail. The primary analysis of ALS-FRS-R at the end of stages 1 to 3 will involve fitting a normal linear mixed model to the data to calculate a mean difference in rate of ALS-FRS-R change between each research treatment and placebo. The pairwise type 1 error rate will be controlled, because each treatment comparison will generate its own distinct and separate interpretation. This publication is based on a formal statistical analysis plan document that was finalised and signed on 18 May 2022. Discussion: In developing the statistical analysis plan, we had to carefully consider several issues such as multiple testing, estimand specification, interim analyses, and statistical analysis of the repeated measurements of ALS-FRS-R. This analysis plan attempts to balance multiple factors, including minimisation of bias, maximising power and precision, and deriving clinically interpretable summaries of treatment effects. Trial registration: EudraCT Number, 2019–000099-41. Registered 2 October 2019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=mnd-smart ClinicalTrials.gov, NCT04302870. Registered 10 March 2020.
- 16 January 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-15
Open AccessStatistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART)
Background: MND-SMART is a platform, multi-arm, multi-stage, multi-centre, randomised controlled trial recruiting people with motor neuron disease. Initially, the treatments memantine and trazodone will each be compared against placebo, but other investigational treatments will be introduced into the trial later. The co-primary outcomes are the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R) functional outcome, which is assessed longitudinally, and overall survival. Methods: Initially in MND-SMART, participants are randomised 1:1:1 via a minimisation algorithm to receive placebo or one of the two investigational treatments with up to 531 to be randomised in total. The comparisons between each research arm and placebo will be conducted in four stages, with the opportunity to cease further randomisations to poorly performing research arms at the end of stages 1 or 2. The final ALS-FRS-R analysis will be at the end of stage 3 and final survival analysis at the end of stage 4. The estimands for the co-primary outcomes are described in detail. The primary analysis of ALS-FRS-R at the end of stages 1 to 3 will involve fitting a normal linear mixed model to the data to calculate a mean difference in rate of ALS-FRS-R change between each research treatment and placebo. The pairwise type 1 error rate will be controlled, because each treatment comparison will generate its own distinct and separate interpretation. This publication is based on a formal statistical analysis plan document that was finalised and signed on 18 May 2022. Discussion: In developing the statistical analysis plan, we had to carefully consider several issues such as multiple testing, estimand specification, interim analyses, and statistical analysis of the repeated measurements of ALS-FRS-R. This analysis plan attempts to balance multiple factors, including minimisation of bias, maximising power and precision, and deriving clinically interpretable summaries of treatment effects. Trial registration: EudraCT Number, 2019–000099-41. Registered 2 October 2019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=mnd-smart ClinicalTrials.gov, NCT04302870. Registered 10 March 2020.
- Open Access
Critical density triplets for the arrestment of a sphere falling in a sharply stratified fluid
We study the motion of a rigid sphere falling in a two-layer stratified fluid under the action of gravity in the potential flow regime. Experiments at a moderate Reynolds number of approximately 20 to 450 indicate that a sphere with the precise critical density, higher than the bottom layer density, can display behaviors such as bounce or arrestment after crossing the interface. We experimentally demonstrate that such a critical sphere density increases linearly as the bottom fluid density increases with a fixed top fluid density. Additionally, the critical density approaches the bottom layer fluid density as the thickness of density transition layer increases. We propose an estimation of the critical density based on the potential energy. With assuming the zero layer thickness, the estimation constitutes an upper bound of the critical density with less than 0.043 relative difference within the experimental density regime 0.997 $g/cm^{3}$ $\sim $ 1.11 $g/cm^{3}$ under the zero layer thickness assumption. By matching the experimental layer thickness, we obtain a critical density estimation with less than 0.01 relative difference within the same parameter regime.Open AccessCritical density triplets for the arrestment of a sphere falling in a sharply stratified fluid
We study the motion of a rigid sphere falling in a two-layer stratified fluid under the action of gravity in the potential flow regime. Experiments at a moderate Reynolds number of approximately 20 to 450 indicate that a sphere with the precise critical density, higher than the bottom layer density, can display behaviors such as bounce or arrestment after crossing the interface. We experimentally demonstrate that such a critical sphere density increases linearly as the bottom fluid density increases with a fixed top fluid density. Additionally, the critical density approaches the bottom layer fluid density as the thickness of density transition layer increases. We propose an estimation of the critical density based on the potential energy. With assuming the zero layer thickness, the estimation constitutes an upper bound of the critical density with less than 0.043 relative difference within the experimental density regime 0.997 $g/cm^{3}$ $\sim $ 1.11 $g/cm^{3}$ under the zero layer thickness assumption. By matching the experimental layer thickness, we obtain a critical density estimation with less than 0.01 relative difference within the same parameter regime.